Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Melanoma”

247 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 247 results

Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Testing effectiveness (Phase 2)Ended earlyNCT01495572
What this trial is testing

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Who this might be right for
Metastatic MelanomaSkin Cancer
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Study completedNCT00679289
What this trial is testing

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Who this might be right for
Metastatic MelanomaCutaneous Melanoma
Ludwig Institute for Cancer Research 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03767348
What this trial is testing

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
Replimune, Inc. 340
Testing effectiveness (Phase 2)Study completedNCT01251978
What this trial is testing

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Who this might be right for
Choroidal Melanoma
New England Retina Associates 10
Testing effectiveness (Phase 2)Study completedNCT04133948
What this trial is testing

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Who this might be right for
Malignant Melanoma Stage III
The Netherlands Cancer Institute 44
Large-scale testing (Phase 3)Active Not RecruitingNCT03553836
What this trial is testing

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 976
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Early research (Phase 1)Ended earlyNCT05909995
What this trial is testing

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Who this might be right for
MelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more
Incyte Corporation 8
Early research (Phase 1)Study completedNCT03538028
What this trial is testing

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Who this might be right for
Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+14 more
Incyte Biosciences International Sàrl 22
Not applicableStudy completedNCT04566302
What this trial is testing

Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy

Who this might be right for
Pigmented LesionsPigmented Skin LesionPigmented Moles+1 more
Massachusetts General Hospital 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT01993719
What this trial is testing

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
National Cancer Institute (NCI) 33
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Early research (Phase 1)Study completedNCT02339324
What this trial is testing

Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b

Who this might be right for
Melanoma
Yana Najjar 31
Very early researchStudy completedNCT00276835
What this trial is testing

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Who this might be right for
Kidney CancerMelanoma (Skin)
Northwestern University 15
Large-scale testing (Phase 3)Active Not RecruitingNCT01274338
What this trial is testing

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Who this might be right for
Melanoma of Unknown PrimaryRecurrent MelanomaStage IIIB Cutaneous Melanoma AJCC v7+2 more
National Cancer Institute (NCI) 1,673
Testing effectiveness (Phase 2)Study completedNCT00003091
What this trial is testing

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Who this might be right for
Kidney CancerMelanoma (Skin)
Hoag Memorial Hospital Presbyterian 40
Not applicableStudy completedNCT00912418
What this trial is testing

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Who this might be right for
Melanoma
Craig L Slingluff, Jr 14
Early research (Phase 1)Study completedNCT04430842
What this trial is testing

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Who this might be right for
AstrocytomaBrain CancerBrain Metastases+20 more
Quadriga Biosciences, Inc. 15
Load More Results